The primary objective is to characterize the programming effects of Boston Scientific Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of Parkinson's disease in acute and chronic settings.

Key Inclusion Criteria:

• Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one (1) of the following: resting tremor or bradykinesia.
• UPDRS III score of >25 in the meds OFF condition
• Medication must improve PD symptoms by ≥30%, as measured by UPDRS subset III score

Key Exclusion Criteria:

• Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator
• Any current drug or alcohol abuse as determined by the investigator
• Any history of recurrent or unprovoked seizures
• Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <12 months

Adverse events up to end of randomized phase (~ up to 120 days post implant)

Adverse events up to end of randomized phase